25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
In one of its latest rulings, the Regional Labor Court of Munich concluded that crowdworkers or micr...
Read More >
What happens if an employer takes adverse action against an employee based on a legitimate, nondiscr...
Read More >
In this episode of Trekking Through Compliance, we consider Where No Man Has Gone Before, which aire...
Read More >
New Jersey businesses will now face an increased slate of potential penalties for misclassification ...
Read More >
Hotels in New Jersey will soon be required to provide panic buttons for employees who work in guest ...
Read More >
As the COVID-19 pandemic continues, owners and developers find themselves facing the prospect of con...
Read More >